Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Prednisone

FDA-approved product (tablet, oral), marketed as Cortan, Delta-Dome, Deltasone and 10 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Prednisone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adrenal gland disease
  • Allergic conjunctivitis
  • Allergic rhinitis
  • Anemia
  • Ankylosing spondylitis
  • Aplastic anemia
  • Arthritis
  • Asthma
  • Atopic eczema
  • Autoimmune thrombocytopenic purpura
  • Berylliosis
  • Brain neoplasm
  • Bursitis
  • Cancer
  • Chorioretinitis
  • Choroiditis
  • and 60 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids acting locally; Corticosteroids; Corticosteroids, weak (group i); Corticosteroids, weak, other combinations
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Prednisone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Prednisone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

    NCT07412470 · start 2026-03-13

    Registered record
    Registry ID
    NCT07412470
    Conditions
    Kidney Transplant Rejection
    Interventions
    Frexalimab; Frexalimab; Tacrolimus; rabbit anti-thymocyte globulin; mycophenolate mofetil; mycophenolate sodium; methylprednisolone; prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2026-03-13
    Completion
    2033-08-15
    Enrolment
    526

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplant Rejection
    InterventionFrexalimab; Frexalimab; Tacrolimus; rabbit anti-thymocyte globulin +4 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

    NCT06392841 · start 2025-10

    Registered record
    Registry ID
    NCT06392841
    Conditions
    Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Deleterious HRR Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; BRIP1 Gene Mutation; CHEK2 Gene Mutation; FANCA Gene Mutation; PALB2 Gene Mutation; RAD51B Gene Mutation; RAD54L Gene Mutation
    Interventions
    Androgen Deprivation Therapy (ADT); Niraparib/Abiraterone Acetate DAT; Abiraterone Acetate; Prednisone; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2025-10
    Completion
    2029-01-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Hormone-sensitive Prostate Cancer (mHSPC); Deleterious HRR Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation +6 more
    InterventionAndrogen Deprivation Therapy (ADT); Niraparib/Abiraterone Acetate DAT; Abiraterone Acetate; Prednisone +1 more
    PhasePhase 2
    Registry statusWithdrawn

  • Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL

    NCT07195799 · start 2024-12-31

    Registered record
    Registry ID
    NCT07195799
    Conditions
    Non-Hodgkin Lymphoma
    Interventions
    Linperlisib combined with CPT regimen; Linperlisib combined with CPT regimen; Linperlisib combined with CPT regimen; Linperlisib combined with CPT regimen; Linperlisib combined with CPT regimen; Linperlisib combined with CPT regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-12-31
    Completion
    2027-12-31
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Hodgkin Lymphoma
    InterventionLinperlisib combined with CPT regimen; Linperlisib combined with CPT regimen; Linperlisib combined with CPT regimen; Linperlisib combined with CPT regimen +2 more
    PhasePhase 2
    Registry statusRecruiting

  • Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

    NCT06470243 · start 2024-11-27

    Registered record
    Registry ID
    NCT06470243
    Conditions
    Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Biospecimen Collection; Bone Scan; Cabazitaxel; Carboplatin; Chest Radiography; Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-11-27
    Completion
    2034-04
    Enrolment
    528

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
    InterventionBiospecimen Collection; Bone Scan; Cabazitaxel; Carboplatin +5 more
    PhasePhase 3
    Registry statusRecruiting

  • Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

    NCT05996185 · start 2024-10-09

    Registered record
    Registry ID
    NCT05996185
    Conditions
    T Cell Lymphoma; T-cell Lymphoma
    Interventions
    Mogamulizumab; DA-EPOCH Protocol; CHOEP protocol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-10-09
    Completion
    2027-11
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionT Cell Lymphoma; T-cell Lymphoma
    InterventionMogamulizumab; DA-EPOCH Protocol; CHOEP protocol
    PhasePhase 2
    Registry statusRecruiting

  • Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

    NCT05958719 · start 2023-03-02

    Registered record
    Registry ID
    NCT05958719
    Conditions
    Peripheral T Cell Lymphoma; Epigenetic Repression
    Interventions
    Chidamide; Azacitidine; liposomal mitoxantrone; prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-03-02
    Completion
    2027-03-02
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral T Cell Lymphoma; Epigenetic Repression
    InterventionChidamide; Azacitidine; liposomal mitoxantrone; prednisone
    PhasePhase 2
    Registry statusRecruiting

  • Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome

    NCT05444946 · start 2022-06-15

    Registered record
    Registry ID
    NCT05444946
    Conditions
    Chronic Pulmonary Aspergillosis; Allergic Bronchopulmonary Aspergillosis
    Interventions
    Prednisone tablet and Itraconazole; Oral itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2022-06-15
    Completion
    2027-02-01
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Pulmonary Aspergillosis; Allergic Bronchopulmonary Aspergillosis
    InterventionPrednisone tablet and Itraconazole; Oral itraconazole
    PhaseNot applicable
    Registry statusRecruiting

  • 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

    NCT05204927 · start 2022-02-14

    Registered record
    Registry ID
    NCT05204927
    Conditions
    Metastasis From Malignant Tumor of Prostate
    Interventions
    177Lu-PSMA-I&T; Abiraterone with Prednisone or Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2022-02-14
    Completion
    2029-02
    Enrolment
    439

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastasis From Malignant Tumor of Prostate
    Intervention177Lu-PSMA-I&T; Abiraterone with Prednisone or Enzalutamide
    PhasePhase 3
    Registry statusActive not recruiting

  • Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)

    NCT04692155 · start 2021-08-31

    Registered record
    Registry ID
    NCT04692155
    Conditions
    Mantle Cell Lymphoma
    Interventions
    Ublituximab; Umbralisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2021-08-31
    Completion
    2022-06-30
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma
    InterventionUblituximab; Umbralisib
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis

    NCT04951986 · start 2021-08-11

    Registered record
    Registry ID
    NCT04951986
    Conditions
    Disseminated Tuberculosis; HIV
    Interventions
    Rifampin; Levofloxacin; Rifampicin, Pyrazinamide, Ethambutol and Isoniazid; Prednisone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-08-11
    Completion
    2026-03
    Enrolment
    732

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDisseminated Tuberculosis; HIV
    InterventionRifampin; Levofloxacin; Rifampicin, Pyrazinamide, Ethambutol and Isoniazid; Prednisone +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

    NCT04421222 · start 2020-06-23

    Registered record
    Registry ID
    NCT04421222
    Conditions
    Prostate Cancer
    Interventions
    EPI-7386 (QD); EPI-7386 (BID); Abiraterone acetate; Apalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2020-06-23
    Completion
    2024-12-03
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionEPI-7386 (QD); EPI-7386 (BID); Abiraterone acetate; Apalutamide
    PhasePhase 1
    Registry statusTerminated

  • Dexamethasone Compared to Non-steroidal Anti-inflammatory Drugs in the Treatment of Acute Pericarditis

    NCT04323280 · start 2020-02-14

    Registered record
    Registry ID
    NCT04323280
    Conditions
    Pericarditis Acute
    Interventions
    Dexamethasone therapy; NSAID therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2020-02-14
    Completion
    2023-07-17
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPericarditis Acute
    InterventionDexamethasone therapy; NSAID therapy
    PhasePhase 4
    Registry statusTerminated

  • PK and Dose Escalation and Expansion Study of DST-2970

    NCT04291664 · start 2020-01-31

    Registered record
    Registry ID
    NCT04291664
    Conditions
    Prostate Cancer
    Interventions
    Abiraterone Acetate; Prednisone 5Mg Tab; DST-2970 (Abiraterone)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2020-01-31
    Completion
    2023-01-27
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionAbiraterone Acetate; Prednisone 5Mg Tab; DST-2970 (Abiraterone)
    PhasePhase 1
    Registry statusTerminated

  • Comparison of Three Modalities to Assess Clinical Competence of Medical Students

    NCT03884114 · start 2019-03-20

    Registered record
    Registry ID
    NCT03884114
    Conditions
    Educational Problems
    Interventions
    High-fidelity simulation; Simulation game; Multiple choice questionnaire
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-03-20
    Completion
    2019-07-06
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEducational Problems
    InterventionHigh-fidelity simulation; Simulation game; Multiple choice questionnaire
    PhaseNot applicable
    Registry statusCompleted

  • Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)

    NCT01893658 · start 2018-06-01

    Registered record
    Registry ID
    NCT01893658
    Conditions
    Acute Interstitial Nephritis
    Interventions
    Omalizumab; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2018-06-01
    Completion
    2018-09-28
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Interstitial Nephritis
    InterventionOmalizumab; Prednisone
    PhasePhase 2
    Registry statusWithdrawn